08 Aug, EOD - Indian

Nifty 50 24363.3 (-0.95)

Nifty Bank 55004.9 (-0.93)

Nifty Midcap 100 56002.2 (-1.64)

SENSEX 79857.79 (-0.95)

Nifty Next 50 65514.7 (-1.24)

Nifty Smallcap 100 17428.2 (-1.49)

Nifty IT 34398.5 (-0.95)

Nifty Pharma 21402.15 (-1.30)

08 Aug, EOD - Global

NIKKEI 225 41820.48 (1.85)

HANG SENG 24858.82 (-0.89)

S&P 6425.5 (0.74)


You are Here : Home > Research

05-Aug-2025

Epigral

Expects capex of Rs 450 crore in FY26


'

Epigral held a conference call on 04 August 2025 to discuss the results for the quarter ended June 2025 and way forward. Mr. Maulik Patel – Chairman and Managing Director, Mr. Kaushal Soparkar – Executive Director, Mr. Sanjay Jain – Chief Financial Officer and Mr. Milind Kotecha – Investor Relations and Strategy of the company addressed the call.

Highlights of the Concall

  • The company mentioned that the chemical industry is on the growth path but a slower pace. Volatility was witnessed in Q1 FY26 and is expected to continue on account of uncertainty on tariffs from the US and also because of the geopolitical situation. However, domestic demand remains strong compared to the global demand.

  • The company reported a revenue degrowth of around 6% in Q1FY26 mainly on account of decreasing volume due to the maintenance work happening at the plant which will end by end of this quarter. It expect optimum capacity utilization to start by end of Q2FY26 beca...



    Pleaselogin & subscribe to view the full report.

    More Reports
    • Company Logo

      (05-Feb-2025)

      Castrol India

      Expects EBITDA margin of 22%-25% for CY25

    • Company Logo

      (10-Feb-2023)

      Deepak Nitrite

      Plans capex of about Rs 1500 crore for FY23 and FY24

    • Company Logo

      (09-Feb-2023)

      Mayur Uniquoters

      Targets revenue of Rs 1000 crore in FY24

    • Company Logo

      (31-Jan-2023)

      Tega industries

      Capex plan is US$ 30-32 million for next three years

  • Analyst Meet / AGM-Conference Call   (05-Aug-2025)

    Epigral

    Expects capex of Rs 450 crore in FY26

  • Results-Analysis   (02-Aug-2025)

    Epigral

    Deferred tax liability benefit boosted profits

  • Analyst Meet / AGM-Conference Call   (06-May-2025)

    Epigral

    Expects sales volume to grow 15-20% over next five years

  • Results-Analysis   (05-May-2025)

    Epigral

    Capex in FY2025 was Rs 195 crore

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +